Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

J&J CAR-T therapy for B-cell lymphoma shows promise in phase 1

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease

A Look at Those With Durable Responses to Epcoritamab in LBCL

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

Breakthrough: J&J's New Dual-Target CAR T Therapy Achieves 80% Complete Response Rate in Advanced Lymphoma

Novel CD19/CD20 CAR T therapy demonstrates exceptional efficacy in large B-cell lymphoma with promising safety profile. See complete trial results.

Global CAR T-Cell Therapy Market Worth US$ 18.1 Bn by 2033

Explore the dynamic growth of the global CAR T-cell therapy market, projected to reach USD 18.1 billion by 2033. Learn about the driving factors behind this expansion, including rising cancer incidence, technological advancements, and increased investments in biotechnology. This comprehensive analysis covers market segmentation, competitive landscape, regulatory challenges, pricing strategies, and future trends, highlighting the potential of CAR…